Rhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI

Journal of Clinical Oncology

Volumn 19, Issue 17, 2001, Pages 3794-

  Van Londen, G J ^a   Mascarenhas, B ^a   Kirkwood, J M ^a  

^a Melanoma Center University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CREATINE KINASE;

ADULT; ALKALINIZATION; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DOSE RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYDRATION; LETTER; PRIORITY JOURNAL; RHABDOMYOLYSIS; TREATMENT OUTCOME;

EID: 0035449606     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.17.3794     Document Type: Letter

References (4)

1. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: Results of intergroup trial E1694/S9512/C509801
2. Rhabdorryolysis after treatment with interferon alpha
3. Fatal rhabdomyolysis and multiple organ failure associated with adjuvant high-dose interferonalpha in malignant melanoma
4. Acute rhabdomyolysis after concurrent administration of interleukin-2, interferon-alpha, and chemotherapy for metastatic melanoma